

DEPARTMENT OF SOCIAL SERVICES

DIVISION OF MEDICAL SERVICES 700 GOVERNORS DRIVE PIERRE, SD 57501-22941

PHONE: 605-773-3495 | FAX: 605-773-5246

WEB: DSS Medicaid Prior Authorizations | EMAIL: DSSMedicaidpa@state.sd.us

KYMRIAH PRIOR AUTHORIZATION REQUEST FORM

This form **MUST BE** submitted with medical records to support services

Date:					
RECEIPIENT INFORMATION					
Medicaid ID:	Date of Birth:		Sex: M F		
Last Name:	<u> </u>	First Name:			
	GENERAL IN	FORMATION			
First Date of Service:		Last Date of Service:			
Primary Diagnosis Code:		HCPC Code:			
Drug Name:	ug Name:		Dose & Frequency:		
Hospitalizations/Treatments/Medications Used in the last 6 months:					
POINT OF CONTACT					
Name and Title:					
Email:	Phone:		Fax:		
Email: Note: The point of contact is the individ regarding the PA. T	lual completing the PA he determination notic	e will be sent to the list	act for questions SD Medicaid may have ted point of contact.		
Email: Note: The point of contact is the individence regarding the PA. T	lual completing the PA he determination notic	and would be the contact will be sent to the list	act for questions SD Medicaid may have ted point of contact.		
Email: Note: The point of contact is the individ regarding the PA. T	lual completing the PA he determination notic	e will be sent to the list	act for questions SD Medicaid may have ted point of contact.		
Email: Note: The point of contact is the individence regarding the PA. T	lual completing the PA he determination notic	e will be sent to the list	act for questions SD Medicaid may have ted point of contact.		
Email: Note: The point of contact is the individence regarding the PA. To RE Name: NPI #: Phone:	Jual completing the PA The determination notice FERRING PROVI	DER INFORMATI Taxonomy: Fax:	act for questions SD Medicaid may have ted point of contact.		
Email: Note: The point of contact is the individence regarding the PA. To RE Name: NPI #: Phone:	Jual completing the PA The determination notice FERRING PROVI	DER INFORMATI Taxonomy:	act for questions SD Medicaid may have ted point of contact.		
Email: Note: The point of contact is the individence regarding the PA. To RE Name: NPI #: Phone: SE Name:	Jual completing the PA The determination notice FERRING PROVI	DER INFORMATI Taxonomy: Fax:	act for questions SD Medicaid may have ted point of contact.		
Email: Note: The point of contact is the individence regarding the PA. To RE Name: NPI #: Phone: SE Name: Address:	Jual completing the PA The determination notice FERRING PROVI	DER INFORMATI Taxonomy: Fax:	act for questions SD Medicaid may have ted point of contact.		
Email: Note: The point of contact is the individence regarding the PA. To RE Name: NPI #: Phone: SE Name:	Jual completing the PA The determination notice FERRING PROVI	DER INFORMATI Taxonomy: Fax:	act for questions SD Medicaid may have ted point of contact.		

CRITERIA				
Medical records to support use of product are submitted				
Initial Therapy (check one)	Yes	No		
Therapy is prescribed by a hematologist or oncologist				
Individual has a diagnosis of or B cell precursor, acute Diffuse large B-cell lym Follicular lymphoma	lymphoblastic leukemia	а		
Individual meets one of the follo	owing regarding diseas	se severity/previous therapy failures:		
 Disease is cla after ≥ 2 cycle chemotherapy Member has head of the properties of the properti	es of chemotherapy (pring for relapsed leukemia had ≥2 relapses apsed or refractory, Philines of chemotherapy the relapsed following allogs out from SCT at the time phoma (including diffurigh-grade B-cell lymphos relapsed or refractory les of systemic therapy disease is relapsed or refractory.	efined as failure to achieve complete response imary refractory) or after 1 cycle of a (chemorefractory) niladelphia chromosome positive (Ph+): member that included 2 tyrosine kinase inhibitors genic stem cell transplantation (SCT) and must me of Kymriah infusion use large B-cell lymphoma (DLBCL) not oma and DLBCL arising from follicular and documentation is provided indicating		
Member has not received Car-T therapy in the past and therapy will not be utilized in conjunction with other Car-T therapies				
Individual is ≥18 years of age if therapy is requested for diffuse large B-cell lymphoma or follicular lymphoma and ≤25 years of age for acute lymphoblastic leukemia				
PHYSICIAN SIGNATURE – PROVIDER ONLY				
Loortify that the information give	This form <u>must be</u> signed	and accurate medical indication for the required		
product	en in mis form is a true	and accurate medical indication for the required		
Name & Title (Printed):		Specialty:		
Signature:				